Compare Mesoblast Limited (MESO) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Omnicom Group Inc. — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Omnicom Group Inc. trades at $82.4 (market cap $23.48B). The key difference: Omnicom Group Inc. is far larger — about 10.8× Mesoblast Limited's market cap, and Omnicom Group Inc. pays a 3.88% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | OMC | |
|---|---|---|
Market Cap | $2.17B | $23.48B |
Sector | Technology | Media |
52-Week High | $20.96 | $85.80 |
52-Week Low | $12.88 | $67.27 |
Enterprise Value | $2.17B | $30.70B |
Dividend Yield | — | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Omnicom (OMC) trades at $82.36, up 0.77% with a bullish technical outlook and strong cash flow generation. The stock shows attractive valuation metrics with a P/E of 12.16 and P/S of 0.95, though 2025 saw a net loss of $54.5 million despite revenue growth to $17.27 billion. Recent developments include major client wins with IBM and Netflix partnerships, positioning the company for future growth in digital advertising.
OMC presents a compelling value opportunity with 28% upside to the $105.75 consensus price target, supported by dividend payments and institutional confidence. Key risks include intense industry competition and the need to sustain profitability improvements after the 2025 loss. The upcoming Q2 2026 earnings report on July 28 will be critical for validating the company's turnaround trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
